Main Street Research buys $11,834,049 stake in Amgen (AMGN)

Amgen (AMGN) : Main Street Research scooped up 2,862 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 11, 2016. The investment management firm now holds a total of 68,397 shares of Amgen which is valued at $11,834,049.Amgen makes up approximately 2.42% of Main Street Research’s portfolio.

Other Hedge Funds, Including , Aston Asset Management added AMGN to its portfolio by purchasing 9,727 company shares during the most recent quarter which is valued at $1,682,966. Amgen makes up approx 0.98% of Aston Asset Management’s portfolio.Highlander Capital Management boosted its stake in AMGN in the latest quarter, The investment management firm added 300 additional shares and now holds a total of 2,200 shares of Amgen which is valued at $380,644. Amgen makes up approx 0.38% of Highlander Capital Management’s portfolio.Autus Asset Management reduced its stake in AMGN by selling 120 shares or 8.26% in the most recent quarter. The Hedge Fund company now holds 1,332 shares of AMGN which is valued at $229,677. Amgen makes up approx 0.05% of Autus Asset Management’s portfolio.Northwest Investment Counselors boosted its stake in AMGN in the latest quarter, The investment management firm added 40 additional shares and now holds a total of 2,497 shares of Amgen which is valued at $413,678. Amgen makes up approx 0.22% of Northwest Investment Counselors’s portfolio.Gradient Investments boosted its stake in AMGN in the latest quarter, The investment management firm added 3,801 additional shares and now holds a total of 30,202 shares of Amgen which is valued at $4,920,812. Amgen makes up approx 0.52% of Gradient Investments’s portfolio.

Amgen opened for trading at $174.44 and hit $175.99 on the upside on Tuesday, eventually ending the session at $174.4, with a gain of 0.03% or 0.05 points. The heightened volatility saw the trading volume jump to 23,76,437 shares. Company has a market cap of $130,514 M.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *